OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD (PR Newswire)
UF startup OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, announced a poster presentation showing encouraging Oxabact®... Read More